AI in Drug Repurposing — Market Forecast and Growth Trajectory
OVERVIEWOverview The global AI in drug repurposing market is projected to reach USD 10.56 billion by 2035, growing at a compound annual growth rate (CAGR) of 23.4%, according to Healthcare Foresights analysis reported by Yahoo Finance. Drug repurposing—identifying new therapeutic uses for existing approved drugs—is an area where AI can dramatically reduce development timelines and costs. Market Drivers AI accelerates drug repurposing by analyzing large biomedical datasets to identify mechanistic connections between existing drugs and new disease targets. This approach bypasses early-stage safety testing for already-approved compounds, reducing the time and cost to clinical validation. The COVID-19 pandemic demonstrated the value of rapid drug repurposing and accelerated investment in AI-powered approaches. Growth Context A 23.4% CAGR over a decade reflects strong but not exceptional growth for a healthcare AI subsegment. The market size projection places AI drug repurposing as a significant but specialized component of the broader AI drug discovery market, which encompasses de novo drug design, target identification, and clinical trial optimization. ---
Subscribe to read full wiki analysis
Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.
View Plans & SubscribeNew users get a 7-day trial — no credit card required.